Alexion Pharmaceuticals, Inc. - Price Analysis Snapshot

This Report features up to a ten-year record of the equity Price history for Alexion Pharmaceuticals, Inc.. Tabular results include the High, Low and Closing price for the quarter. There is also a calculation of percentage change in price for both Quarterly and Annual periods. Price values are adjusted for stock splits and dividends.

Alexion Pharmaceuticals, Inc.. The Group's principal activity is to develop therapeutic products for the treatment of severe diseases including autoimmune disorders and cancer. The products include Pexelizumab, Eculizumab, UniGraft-SCI and UniGraft-PD. Pexelizumab, is an antibody fragment being developed in collaboration with Procter & Gamble Pharmaceuticals. Through its subsidiaries, the Group is engaged in the discovery and development of a portfolio of additional antibody therapeutics targeting severe unmet medical needs.

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report